Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Capital Expenditures (2016 - 2026)

Integra Lifesciences Holdings' Capital Expenditures history spans 17 years, with the latest figure at $17.2 million for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 41.84% to $17.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $81.4 million, a 22.01% decrease, with the full-year FY2025 number at $81.4 million, down 22.01% from a year prior.
  • Capital Expenditures hit $17.2 million in Q4 2025 for Integra Lifesciences Holdings, up from $15.2 million in the prior quarter.
  • Over the last five years, Capital Expenditures for IART hit a ceiling of $29.7 million in Q2 2024 and a floor of $6.6 million in Q2 2021.
  • Historically, Capital Expenditures has averaged $17.2 million across 5 years, with a median of $15.3 million in 2024.
  • The widest YoY moves for Capital Expenditures: up 225.47% in 2021, down 59.59% in 2021.
  • Tracing IART's Capital Expenditures over 5 years: stood at $27.4 million in 2021, then plummeted by 47.29% to $14.5 million in 2022, then skyrocketed by 69.72% to $24.5 million in 2023, then grew by 20.64% to $29.6 million in 2024, then tumbled by 41.84% to $17.2 million in 2025.
  • Business Quant data shows Capital Expenditures for IART at $17.2 million in Q4 2025, $15.2 million in Q3 2025, and $20.1 million in Q2 2025.